लेम्बोरेक्सेंट के इंटरैक्शन

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ओलिसेरिडिन लेबल, बॉक्स्ड चेतावनी)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (क्लोरप्रोमाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product excitability may occur, especially in children drowsiness may occur avoid alcoholic beverages alchohol, sedatives and tranquilizers… (क्लोरफेनिरामिन लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (गैबापेंटिन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (टेपेंटाडोल लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage. (ट्राइफ्लुओपेराज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

…breathing problem such as emphysema or chronic bronchitis • glaucoma • trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking • a sedative or any other sleep-aid • tranquilizers • any other antihistamines • any other drugs When using this product • avoid alcoholic beverages • do not drive a motor vehicle or operate… (डॉक्सीलामिन लेबल, चेतावनियां)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (नालबुफिन लेबल, बॉक्स्ड चेतावनी)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown… (परफेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (पेंटाज़ोसिन और नालोक्सोन लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. (प्रोक्लोरपेराज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. (फ्लुफेनाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (बेलाडोना और ओपियम लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूप्रेनॉर्फिन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (मॉर्फिन लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (रेमिफेंटानिल लेबल, बॉक्स्ड चेतावनी)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (लेवॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid alcohol consumption with DAYVIGO [see Warnings and Precautions ( 5.1 )]. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (हाइड्रोमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Examples: Strong CYP3A inhibitors: itraconazole, clarithromycin Moderate CYP3A inhibitors: fluconazole, verapamil Weak CYP3A inhibitors: chlorzoxazone, ranitidine Strong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy [see Clinical Pharmacology… (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Examples: Strong CYP3A inhibitors: itraconazole, clarithromycin Moderate CYP3A inhibitors: fluconazole, verapamil Weak CYP3A inhibitors: chlorzoxazone, ranitidine Strong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy [see Clinical Pharmacology… (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Risk increases with dose and use with other central nervous system (CNS) depressants. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (डॉक्साप्राम लेबल, चेतावनियां)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (प्राज़ोसिन लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)